Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Sinclair Pharma Plc

30 Mar 2016 10:31

KILLIK & CO LLP - Form 8.3 - Sinclair Pharma Plc

KILLIK & CO LLP - Form 8.3 - Sinclair Pharma Plc

PR Newswire

London, March 30

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Killik & Co LLP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeSinclair Pharma Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure29/03/2016
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:5,457,2071.10
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:5,457,2071.10

\* The change in the holding of 36,073 shares since the last disclosure on 28th March 2016 date is due to transfer out of a discretionary holding.

All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
Ord GBP0.01Purchase183,58233.5p
Ord GBP0.01Purchase329,52533.696p

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?No

Date of disclosure:30/03/2016
Contact name:Heidi Richer
Telephone number:020 7337 0400

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
4th Jan 20163:01 pmRNSForm 8.3 - Sinclair Pharma plc
4th Jan 201610:06 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
31st Dec 201511:40 amRNSForm 8.3 - Sinclair Pharma plc
31st Dec 20157:38 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
30th Dec 20159:30 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
29th Dec 201511:31 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
29th Dec 201511:30 amRNSForm8.5(EPT/RI)-Sinclair IS Pharma PLC-Replacement
24th Dec 201510:57 amRNSForm 8.3 - Sinclair Pharma plc
24th Dec 20158:20 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
23rd Dec 201512:46 pmRNSForm 8.3 - Sinclair IS Pharma plc
23rd Dec 201511:23 amRNSPosting of Annual Report and Notice of AGM
23rd Dec 20157:47 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
22nd Dec 20152:57 pmRNSForm 8.3 - Sinclair IS Pharma plc
22nd Dec 20157:31 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
21st Dec 20158:16 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
18th Dec 201512:18 pmRNSForm 8.3 - Sinclair IS Pharma plc
18th Dec 20159:08 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
17th Dec 201512:13 pmRNSForm 8.3 - SINCLAIR IS PHARMA PLC
17th Dec 20158:41 amRNSCompletes £132m strategic disposal
17th Dec 20158:26 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
16th Dec 20153:05 pmRNSForm 8.3 - Sinclair IS Pharma plc
16th Dec 20157:55 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
15th Dec 20159:09 amRNSForm 8.5 (EPT/RI) _Sinclair IS Pharma Plc
14th Dec 20159:35 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
11th Dec 201511:17 amBUSForm 8.3 - Sinclair IS Pharma Plc
11th Dec 20157:53 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
10th Dec 20158:02 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
9th Dec 20158:55 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
8th Dec 20152:41 pmRNSForm 8.3 - SINCLAIR IS PHARMA PLC
8th Dec 201512:00 pmBUSForm 8.3 - Sinclair IS Pharma Plc
8th Dec 201511:22 amRNSForm 8.3 - Sinclair IS Pharma plc
8th Dec 20159:12 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
7th Dec 20157:51 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
4th Dec 201511:35 amBUSForm 8.3 - Sinclair IS Pharma Plc
4th Dec 201511:17 amRNSForm 8.3 - Sinclair IS Pharma plc
4th Dec 20158:29 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
3rd Dec 201512:06 pmRNSForm 8.3 - Sinclair IS Pharma plc
3rd Dec 201511:49 amBUSForm 8.3 - Sinclair IS Pharma Plc
3rd Dec 20158:19 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
2nd Dec 20151:51 pmRNSForm 8.3 - Sinclair IS Pharma plc
2nd Dec 201512:00 pmBUSForm 8.3 - Sinclair IS Pharma Plc
2nd Dec 20158:44 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
1st Dec 20151:27 pmRNSForm 8.3 - Sinclair IS Pharma plc
1st Dec 201511:41 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
30th Nov 20153:02 pmRNSHolding(s) in Company
30th Nov 20151:11 pmRNSForm 8.3 - Sinclair IS Pharma plc
30th Nov 201511:59 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
27th Nov 20151:32 pmRNSForm 8.3 - Sinclair IS Pharma plc
27th Nov 20159:04 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC
26th Nov 20158:28 amRNSForm 8.5 (EPT/RI) - Sinclair IS Pharma PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.